Clinical Trial Update: RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid [Phase 2]

View source ↗

Summary

A Phase 2 trial of RAD001 (everolimus) for pheochromocytoma, extra-adrenal paraganglioma, and non-functioning carcinoid has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumor
• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• Afinitor (everolimus)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Pheochromocytoma, Extra-adrenal Paraganglioma | Phase 2 | Status: COMPLETED